Tissue Engineering Market Set to Grow at 14-15% CAGR by 2029, Driven by Advances in Regenerative Medicine and 3D Bioprinting

The Global Tissue Engineering Market is expected to witness a growth rate of 14-15% in the next five years. Rising incidence of degenerative bone diseases, diabetic ulcers, traumatic injuries, sports injuries, and chronic diseases; shortage of organ and tissue supply; and advancement in tissue engineering technologies such as 3D printing, use of smart biomaterials, induced pluripotent stem cells (iPSCs), and microfluidics are some of the key factors fostering tissue engineering market growth. However, clinical translation of tissue-engineered products is challenging largely due to factors such as scalability, cost, and regulatory issues that are likely to hinder market growth.

Tissue and organs may lose their function and structure due to age, diseases, trauma, surgical removal, and congenital defects. Tissue engineering combines cells, scaffolds, and growth factors to regenerate tissues or replace damaged or diseased tissues. This can be achieved either ex vivo or in situ by using various molecules, materials, or cells to stimulate local tissue regenerative capacity. Tissue engineering is increasingly gaining traction in the medical field with the growing need to restore, maintain, or improve damaged tissues or whole organs.

Explore market trends, size, share and growth report - request a sample copy: https://meditechinsights.com/tissue-engineering-market/request-sample/

Shortage of Organs and Tissues to Drive Market Growth

With the intensifying aging of the world population, there is an increasing demand for organ replacements. Kidneys are the most frequently transplanted organ and help patients with end-stage kidney disease. Some other frequently transplanted organs include livers, lungs, and hearts. While organ transplantation is increasingly used as medical treatment, a shortage of organs is a major concern. Many patients die every day while waiting for a transplant due to the shortages in organ and tissue supply. For instance, 5600 people in the US die each year while on the transplant waiting list (Donate Life America); and in 2022, an average of 19 patients died every day while waiting for an organ transplant in Europe (EU Commission). This shortage of organs, tissues, and cells has boosted the development and demand for tissue engineering as it aims at producing functional tissue constructs for use in the reconstruction or regeneration of damaged or lost tissues and organs.

Orthopedics and Musculoskeletal Disorders - A Major Application Area of Tissue Engineering

Application areas of tissue engineering include orthopedics & musculoskeletal disorders, cardiovascular diseases, dental & maxillofacial disorders, dermatology & wound care, neurology, and among others. Currently, tissue-engineered products are significantly used in orthopedics and musculoskeletal disorders to address bone regeneration and repair clinical needs. As musculoskeletal disorders are most prevalent in the elderly, the world's aging population represents the major contributing factor to the increasing medical and socioeconomic burdens of treating musculoskeletal impairments. Approximately, 1.71 billion people have musculoskeletal conditions worldwide (WHO). Tissue engineering is a promising strategy for structural support for new bone formation. With the growing burden of orthopedic and musculoskeletal injuries and the availability of advanced tissue-engineered products, the demand for tissue engineering is likely to further propel the market growth.

"Tissue engineering has widespread applications in bone, periodontal tissue defects, skin repairs, and corneal transplantation. However, with technological advancements and growing research in this field, we see tremendous progress in the use of tissue engineering in areas such as neuroscience and cardiovascular in the future."

"- Manager of Marketing & Business Development, A Leading Tissue Engineering Company, United States

Trend Towards 3D Printing

The field of tissue engineering continues to evolve with recent developments in processing techniques. Some of the conventional techniques that have been used to develop scaffolds, matrices, or tissue constructs include salt leaching, molding, spinning, freeze-drying, solvent casting and particulate leaching, electrospinning, and selective laser sintering. However, recently 3D printing has been gaining increasing popularity owing to several advantages over other tissue engineering techniques including the creation of well-defined, customized structures that mimic native tissues, and cost-effectiveness, among others. Different combinations of various fabrication techniques are being used such as combining electrospinning with 3D bioprinting to produce advanced scaffolds.

US Expected to be a Major Growth Engine in the Tissue Engineering Market

The US is expected to be a major growth engine in the tissue engineering market due to several key factors. The country's advanced healthcare infrastructure and significant involvement in research and development activities support the development and adoption of advanced treatment options like tissue engineering. The US also faces a significant burden of an aging population and chronic diseases, driving demand for solutions that improve patient health and reduce healthcare costs. Moreover, the US has a presence of big companies involved in tissue engineering such as Integra Lifesciences, J&J Services, NuVasive, Stryker, and BioTissue, among others, further improving product availability and growth.

Product Type Segment Analysis

The tissue engineering market comprises cells, scaffolds, and other products. Tissue engineering often begins with a scaffold, which may utilize material from naturally occurring proteins to biocompatible synthetic polymers. Scaffolds are the largest product segment wherein the use of Synthetic Materials is greater as compared to Natural Materials. On the other hand, Cells form the basis of tissue engineering. Depending on the application, cells can be derived from various sources such as Autologous Cells (derived from the same individual), Allogeneic Cells (sourced from a donor of the same species), and Xenogeneic Cells (obtained from a different species, typically used for research).

End-user Type Segment Analysis

The tissue engineering market can be analyzed based on end-user types, such as Hospitals, Ambulatory Surgery Centers (ASCs), Specialty Care Clinics, and Others. Hospitals represent the largest segment as they are well-equipped to handle the complexity of patient care and manage high patient volumes. However, specialty care clinics and ASC segments are likely to witness faster growth driven by the growing number of ASCs and increasing procedures performed at these centers.

Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in the Market

Players operating in this market are adopting both organic and inorganic growth strategies such as collaborations, acquisitions, and new product launches to garner market share. For instance,

In July 2024, MiMedx Group, Inc. launched HELIOGENTM Fibrillar Collagen Matrix, a particulate xenograft product aimed at addressing complex wounds primarily in the surgical setting. HELIOGEN is a shelf-stable offering that contains Type I and Type III collagen and mimics the native composition of structural connective tissue

In January 2024, Cellular Logistics Inc. and Allele Biotechnology Inc. collaborated to develop regenerative medicine products to treat ischemic heart disease. Cellular Logistics' SolusTM, is a highly promising formulation of a regenerative medicine biomaterial designed to minimize injury and revitalize damaged heart tissue for patients suffering a heart attack. Clinical development of SolusTM will utilize ALLELE's GMP-grade iPSC lines embodying the company's IP-protected mRNA-based cell reprogramming technology

In January 2023, BioMed X and AbbVie extended research collaboration in the US focused on the development of a new tissue engineering platform to produce complex human ex vivo models (disease-on-a-chip) from primary human cells and tissues to study human tissue inflammation

The tissue engineering market is expected to gain further momentum in the coming years due to technological advancements, rising R&D investments, and aggressive organic and inorganic growth strategies followed by the players.

Competitive Landscape Analysis

The global Tissue Engineering market is marked by the presence of established and emerging market players such as Integra LifeSciences Corporation, Medtronic, AbbVie, BioTissue, NuVasive, J&J Services, Organogenesis, Stryker, Terumo, Matricel (Nobel Biocare), Regrow Biosciences, Mallinckrodt Pharmaceuticals, Sumitomo Pharma, CollPlant Biotechnologies, Mimedx, Smith+Nephew, Cellular Logistics, Japan Tissue Engineering, Lattice Medical, Tissue Regenix, and Vericel Corporation, among others.

Explore the latest trends and deep insights in just one click: https://meditechinsights.com/tissue-engineering-market/

Future Outlook of the Tissue Engineering Market

The global tissue engineering market is expected to gain further momentum in the coming years due to the growing research and application areas of tissue-engineered products, advancement in fabrication techniques such as 3D printing, availability of smart biomaterials, organ-on-chip technology, among others. These factors collectively contribute to the growth and evolution of the tissue engineering market.

Latest Healthcare & Pharma Industry Research Reports

Smart Pills Market: https://meditechinsights.com/smart-pills-market/

AI in Precision Medicine Market: https://meditechinsights.com/ai-in-precision-medicine-market/

Anti-aging Market: https://meditechinsights.com/anti-aging-market/

Contact:

Ruta Halde
Associate, Medi-Tech Insights
Phone: +32 498 86 80 79
Email: info@meditechinsights.com
Website: https://meditechinsights.com/

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services in the areas of market assessments, due diligence, competitive intelligence, market sizing and forecasting, pricing analysis & go-to-market strategy. Our methodology includes rigorous secondary research combined with deep-dive interviews with industry-leading CXO, VPs, and key demand/supply side decision-makers.

This release was published on openPR.